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ABSTRACT
Background Physicians treating acute pulmonary
embolism (PE) are faced with difﬁcult management
decisions while speciﬁc guidance from recent guidelines
may be absent.
Methods Fourteen clinical dilemmas were identiﬁed by
physicians and haematologists with speciﬁc interests in
acute and chronic PE. Current evidence was reviewed
and a practical approach suggested.
Results Management dilemmas discussed include: sub-
massive PE, PE following recent stroke or surgery,
thrombolysis dosing and use in cardiac arrest, surgical or
catheter-based therapy, failure to respond to initial
thrombolysis, PE in pregnancy, right atrial thrombus, role
of caval ﬁlter insertion, incidental and sub-segmental PE,
differentiating acute from chronic PE, early discharge and
novel oral anticoagulants.
Conclusion The suggested approaches are based on a
review of the available evidence and guidelines and on
our clinical experience. Management in an individual
patient requires clinical assessment of risks and beneﬁts
and also depends on local availability of therapeutic
interventions.
INTRODUCTION
Several guidelines on acute pulmonary embolism
(PE) have been published.1–3 Guidance for various
scenarios which challenge physicians in the man-
agement of acute PE are often not easily accessible
in guidelines. Our institution runs an integrated PE
service between respiratory and haematology physi-
cians and a large tertiary pulmonary hypertension
service. We are not infrequently referred complex
acute PE cases from other centres. In this review
we discuss the most clinically challenging scenarios.
METHODS
Eight physicians with an interest in the manage-
ment of acute and chronic pulmonary embolic
disease compiled a list of 14 challenging clinical
issues faced in their day-to-day practice. A PubMed
search for each dilemma was performed, an initial
review and suggested approach drafted followed by
round-table discussion to achieve consensus regard-
ing management. In many dilemmas, conclusions
based on the available literature, were hampered by
patient numbers and reporting bias. Suggested
approaches were provided based on consensus.
DEFINITION OF PE SEVERITY
In the current paper we have adopted the American
Heart Association (AHA) classiﬁcation.3 Massive PE
is deﬁned as sustained hypotension (systolic blood
pressure <90 mm Hg) for >15 min secondary to
acute PE or a requirement of inotropes or signs of
shock. Submassive PE is deﬁned by evidence of right
ventricular (RV) dysfunction and/or evidence of
myocardial necrosis. Patients with none of these fea-
tures are deﬁned as low-risk.
CLINICAL DILEMMAS
Which patients with submassive PE should I
thrombolyse?
The pro–con debate published in this issue of
Thorax highlights the controversy regarding sys-
temic thrombolytics in normotensive patients with
PE.4 5 Clinical trials have demonstrated more rapid,
immediate haemodynamic improvement and clot
resolution following thrombolysis, but not clear
mortality beneﬁts.6 7 Recent data from a large unse-
lected national registry demonstrated that thromb-
olysis in normotensive patients with acute PE was
associated with increased mortality.8 Consideration
for thrombolysis therefore requires risk stratiﬁca-
tion. Validated severity scoring systems, such as the
PE Severity Index (PESI, table 1), can identify clin-
ical features at the time of presentation associated
with poorer outcome.9 European Society of
Cardiology (ESC) guidelines suggest assessing for
RV dysfunction (using echocardiography, CT or
B-type natriuretic peptide) or ischaemia (troponin)
to aid risk stratiﬁcation.1 The presence of lower
limb deep venous thrombosis (DVT) has also been
associated with poorer survival.10 By combining
these factors it is possible to identify a higher risk
population with 30-day mortality >20% (table 2).11
A meta-analysis of randomised controlled trials
(RCTs) of thrombolysis in massive and submassive
PE published prior to 2004 reported a risk of major
Table 1 PE severity index (adapted from Aujesky
et al9)
Predictor Points
Demographic
Age, per year Age, in years
Men +10
Comorbidities
Cancer +30
Heart failure +10
Chronic lung disease +10
Clinical findings
Pulse ≥110 +20
Systolic blood pressure <100 mm Hg +30
Respiratory rate ≥30 +20
Temperature <36 +20
Altered mental status +60
Saturations <90% +20
Total points: ≤65 class I (very low risk), 66–85 class II (low risk),
86–105 class III (intermediate risk), 106–125 class IV (high risk),
≥126 class V (very high risk).
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bleeding of 9.1% and intracranial haemorrhage (ICH) of 0.5%
while a recent large RCT of tenecteplase in submassive PE
(PEITHO) observed rates of major bleeding of 6.3% and ICH of
2% (compared with 1.5% and 0.2% respectively for heparin
alone).12 Interestingly, bleeding risk was lower and mortality
beneﬁt higher in patients <75 years.
Suggested approach: In submassive PE we would not routinely
administer thrombolysis. PESI score and the presence or absence
of single or multiple poor prognostic factors should be balanced
against factors associated with increased risk of bleeding (includ-
ing age) in identifying suitable candidates for thrombolysis.
What is the risk of thrombolysis in a patient with recent
surgery, previous stroke or intracranial space-occupying lesion?
Thrombolysis after recent surgery
We identiﬁed 25 reports, including 64 patients, thrombolysed
(the majority for PE) following major recent surgery13–37 (see
online supplementary table S3). Major bleeding occurred in
>50% of patients receiving thrombolysis within 1 week of
surgery and in 20% of patients thrombolysed 1–2 weeks post-
operatively. American College of Chest Physicians (ACCP)
guidelines suggest that recent surgery (excluding recent brain or
spinal surgery or trauma) is a relative contraindication and that
the bleeding risk reduces signiﬁcantly 2 weeks after surgery.
Thrombolysis in the presence of intracranial
space-occupying lesions
A review of 12 patients with intracranial neoplasms thrombolysed
for various indications identiﬁed ICH in a single patient (8.3%).38
Guillan et al39 identiﬁed ﬁve cases (ﬁve meningiomas, one choles-
teatoma and one paranasal tumour) receiving systemic thromboly-
sis for stroke without complications. The risk of ICH is dependent
on tumour type and localisation. A clinicopathological study
showed the risk of microscopic and macroscopic spontaneous
bleeding to be 50% in metastatic melanoma and ranging from
29.2% in oligodendroglioma to 2.8% in meningioma.40
Thrombolysis after recent ischaemic stroke
Previous ischaemic stroke within 3 or 6 months is a contraindi-
cation to thrombolysis in ACCP and ESC guidelines.1 2 A study
involving 145 patients with a stroke within 3 months who
received thrombolysis for a further stroke did not show an
increase in ICH rate.41
Suggested approach: In patients with a massive PE within
1 week of surgery we would favour mechanical treatment if
available. Within 1–2 weeks following surgery, thrombolysis may
be an acceptable risk depending on the nature of the surgery. In
our opinion previous ischaemic stroke is not an absolute contra-
indication to thrombolysis but there are no data to guide an
acceptable timescale since the stroke. Selected intracranial space-
occupying lesions, for example meningiomas, would not inﬂuence
our decision to thrombolyse.
A patient with an acute cerebral infarct is found to have an
acute PE: what should I do regards anticoagulation?
Patients rarely present with a stroke and PE simultaneously due
to paradoxical embolisation across a patent foramen ovale
(PFO).42 43 More frequently (1–10% of cases) patients may
develop an acute PE following a stroke.44 PE is the most
common cause of death 2–4 weeks post stroke.44 In the absence
of anticoagulation, the majority of haemorrhagic transformation
involves petechial bleeds with low risk of mass effect.45–47
However, low and intermediate dose heparin early after stroke
presentation is associated with an increased rate of haemor-
rhagic transformation.48–50 Stroke guidelines advise delaying
anticoagulation for 2 weeks post ischaemic stroke in patients
with atrial ﬁbrillation but give discordant advice regarding antic-
oagulation for coexisting PE. UK stroke guidance suggests antic-
oagulation for proximal DVT or PE while AHA guidelines do
not recommend initial anticoagulation in patients with moderate
to severe stroke.51 52
Suggested approach: The risk–beneﬁt ratio for individual
patients should be assessed; however, our general approach is to
anticoagulate all patients with a cerebral infarct and PE. In
patients with PE with a primary haemorrhagic stroke or recent
signiﬁcant haemorrhagic transformation we would consider
inferior vena cava (IVC) ﬁlter insertion and delayed
anticoagulation.
What is the optimal type and dose of thrombolytic agent
and what should I do if a patient is already on low
molecular weight heparin?
Thrombolytic agents for PE should be administered
peripherally.2 Several thrombolytic agents have been studied:
urokinase, streptokinase and recombinant tissue plasminogen
activators (alteplase, reteplase, desmoteplase and tenecteplase).2 3
Alteplase is the most widely used thrombolytic agent for PE;
recommended dosing in patients ≥65 kg is a loading bolus of
10 mg over 1–2 min followed by 90 mg infused over 2 h.53 In
patients <65 kg the total dose administered is 1.5 mg/kg; for
example a patient weighing 60 kg should receive a 10 mg
loading bolus followed by 80 mg over 2 h. In patients already
receiving intravenous heparin we stop the infusion prior to
administration of alteplase, check activated partial thromboplas-
tin time (APTT) 2 h following completion of administration and
restart heparin when the APTT ratio is <2× the upper limit of
normal. If there is good clinical response to thrombolysis we
would convert to low molecular weight heparin (LMWH) 24 h
following thrombolysis. If therapeutic LMWH had been admi-
nistered prior to thrombolysis we would usually start heparin
infusion as above but delay commencement to 18 h following
the last dose of LMWH if once-daily dosing and 8–10 h if
twice-daily dosing had been used. Two RCTs have investigated
the efﬁcacy and side effects of half-dose alteplase in predomin-
antly submassive PE.54 55 Superior efﬁcacy with no increase in
bleeding risk was observed when compared with anticoagulation
alone,54 and equal efﬁcacy with less haemorrhage was seen
when compared with standard-dose anticoagulation.55
Table 2 Clinical, laboratory and echo parameters predicting
30-day PE-related mortality in normotensive patients (adapted from
Jimenez et al11)
PPV (%)
Trop 10.5
RVD 11.7
DVT 9.6
Trop and RVD 15.2
Trop and DVT 17.1
RVD and DVT 19.6
Trop, RVD and DVT 20.8
High-risk PESI, Trop and RVD 20.7
High-risk PESI, Trop and DVT 24.4
High-risk PESI, RVD and DVT 25.0
DVT, deep venous thrombosis on compression ultrasound; PESI, PE severity index;
PPV, positive predictive value; RVD, right ventricular dysfunction on echocardiography;
Trop, elevated troponin I.
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Suggested approach: If thrombolysis is indicated for PE we
would administer a 10 mg bolus of alteplase followed by a
further 90 mg over 2 h (up to a maximum of 1.5 mg/kg). If
thrombolysis is indicated but there is a high risk of haemorrhage
we would consider using a half-dose regimen.
Which patients in an arrest or peri-arrest situation should I
consider thrombolysing in the absence of deﬁnitive
radiological evidence of PE?
If PE is suspected clinically in an acutely deteriorating patient
who is too unwell for CT pulmonary angiogram (CTPA) then
echocardiography may identify signs of acute right heart strain
suggestive of acute PE.56 57 Thrombolysis can increase the
return of spontaneous circulation and survival to discharge in
patients with known or suspected PE who have cardiac
arrest.58–60 British Thoracic Society guidelines suggest a bolus
dose of 50 mg alteplase in the peri-arrest or arrest situation.61
Patients who have arrested and then regained circulation may
also be suitable for emergency pulmonary embolectomy.62
Patients in whom the cause of arrest is unclear should not
receive thrombolysis during cardiopulmonary resuscitation.2 A
recent large RCT demonstrated that thrombolysis in
out-of-hospital cardiac arrest when the cause of arrest is undif-
ferentiated is not associated with signiﬁcant mortality beneﬁt.63
Suggested approach: Thrombolysis should be administered in
the peri-arrest or arrest situation when PE is either known or
suspected.
I feel it is too unsafe to perform thrombolysis: what are the
surgical and non-surgical alternatives?
If thrombolytic therapy is contraindicated and a patient has sig-
niﬁcant accessible PE and persisting haemodynamic compromise
then embolectomy, performed by an open surgical or catheter-
based approach, should be considered.1 Older case series
observed mortality rates for surgical embolectomy of >20%;3
however an intraoperative mortality of 6% was reported in 47
consecutive patients.64 Catheter-directed therapies include
mechanical disruption of thrombi by catheter, ultrasound or
pressurised saline injection.65 Suction may be used to perform
thrombectomy or aspirate fragments of macerated emboli fol-
lowing other techniques. A recent meta-analysis observed 87%
clinical success.66 Local intra-clot thrombolytic was used in 67%
of cases and was associated with superior clinical success, postu-
lated due to increased thrombus surface area exposed to
thrombolysis after fragmentation. Major complications of
catheter-directed therapy including pulmonary artery rupture
and massive haemoptysis were seen in 2.4% of cases while
haemodynamic deterioration due to fragmented emboli was
unpredictable.66 Although the incidence of major bleeding in
the meta-analysis was low (18 non-cerebral haemorrhages
requiring transfusion and 1 intra-cerebral haemorrhage reported
in 594 patients66) the absolute risk of bleeding related to intra-
clot thrombolysis in an individual patient with a contraindica-
tion to systemic thrombolysis is not clear. There are few data
comparing thrombolysis, surgical embolectomy and catheter-
based intervention as primary treatment for massive PE. Current
guidelines restrict surgical embolectomy to situations when
thrombolysis has failed or is contraindicated.1 Although there is
increasing interest in the expansion of surgical embolectomy to
the initial management of massive PE, randomised trial data are
required.62 64 67–70
Suggested approach: No comparative data exist to guide
primary management of massive PE in the presence of a strong
contraindication to systemic thrombolysis. Management is
dependent on local availability of cardiothoracic surgery and
catheter-based therapy.
A patient with a recent acute PE fails to respond to initial
therapy: what should I do?
If a patient with acute PE fails to respond to initial anticoagula-
tion, with worsening cardiovascular instability and/or respira-
tory failure, then thrombolysis should be considered. In the
MAPPET-3 study of submassive PE, delayed thrombolysis was
performed in 23% of patients treated initially with heparin,
with no difference in mortality compared with patients receiving
up-front thrombolysis.6 Although reperfusion is greater the
earlier thrombolysis is given, beneﬁt may be observed when
administered up to 14 days from symptom onset.71 Failure to
improve following thrombolysis may be related to persistent
thrombus, complications such as lung infarction or infection or
existence of chronic clot. Reassessment with additional imaging
may therefore be required. In the presence of persistent clot,
repeat thrombolysis or mechanical therapy may be considered.
A single centre retrospective study of treatment in failed
thrombolysis demonstrated that mortality in patients receiving
repeat thrombolysis was 38% compared with 7% in patients
undergoing embolectomy, although bias in management
approach cannot be excluded.72 Supportive therapy for lung
infarction may include ventilatory support, treatment of super-
added infection and inotropic support. If underlying chronic
thromboembolic disease is suspected, referral for pulmonary
endartectomy and the use of bridging pulmonary vasodilator
therapy should be considered. The role of pulmonary vasodila-
tors in purely acute disease has also been assessed.73 Inhaled
nitric oxide may improve gas exchange in acute PE.74 75 Limited
data suggest possible beneﬁt from nebulised iloprost 76 77 while
a small RCT failed to demonstrate beneﬁt from intravenous
eposprostenol.78 There are limited reports of beneﬁt from silde-
naﬁl in animal models and humans with acute PE.79
Suggested approach: Thrombolysis should be considered
when a patient initially treated with anticoagulation alone devel-
ops worsening cardiovascular instability or respiratory failure.
Failure to improve following thrombolysis should trigger
reassessment for residual clot or complication of PE. Surgical
embolectomy is preferable to re-thrombolysis for persistent
obstructing acute PE.
How should I manage a pregnant patient with signiﬁcant
PE?
In non-massive PE, therapeutic LMWH has been shown to be
safe and effective at preventing recurrent PE and does not cross
the placenta.80 Warfarin administration is teratogenic in the ﬁrst
trimester but is also associated with neural abnormalities during
any trimester and UK obstetric guidelines advise against its use
during pregnancy.81 82 If PE is within a month of the expected
date of delivery then a retrievable IVC ﬁlter should be inserted.
A recent review identiﬁed 189 pregnant patients receiving
thrombolysis for venous thromboembolism (VTE); major bleed-
ing occurred in 2.6% with no maternal mortality.83 The peri-
partum period poses a challenge with greater risk of haemor-
rhage associated with thrombolysis. The use of mechanical dis-
ruption, lower-dose catheter-directed thrombolysis and surgical
embolectomy has been described and is dependent on local
availability.30 84 85
Suggested approach: Therapeutic LMWH is the anticoagulant
of choice in pregnancy. Systemic thrombolysis should be admi-
nistered for massive PE in pregnancy; however if bleeding risk is
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high (eg, in the peripartum period) then surgical or mechanical
methods are suggested, depending on local availability.
An echo demonstrates thrombus in the right atrium: what is
the optimal management?
Right atrial thrombus occurs in 4–8% of patients with acute
PE.86–90 Two main types of thrombus have been described: type
A has high early mortality and consists of long, thin, worm-like
mobile thrombi associated with clinically severe PE.91 Low
cardiac output, higher pulmonary arterial pressure and more
severe tricuspid regurgitation may slow transit of clot from per-
ipheral veins to the pulmonary vasculature.90 Type B consists of
immobile, non-speciﬁc thrombi with absence of associated PE in
60% of cases and low early mortality. A small proportion of
thrombi are intermediate in character (type C), being mobile but
not worm-like in shape, and have the potential to obstruct right
atrial or ventricular outﬂow.91–93 CTPA is highly effective at
identifying type A thrombi with a sensitivity of 100%, although
false positives may be observed in patients with non-dilated
right ventricles due to incomplete contrast ﬁlling.89 The optimal
management of patients with right atrial thrombus is unclear.
Two-week mortality in 42 patients treated with heparin,
thrombolysis or surgical embolectomy was equally poor
(20–25%).86 A systematic review of 177 cases observed lower
mortality in patients receiving thrombolysis (11%) compared
with anticoagulation (29%) and surgery (24%).94 In a series of
16 consecutively thrombolysed patients, right atrial thrombus
disappeared in all patients within 24 h with 30-day survival of
100%.90 In a minority of patients thrombus may straddle a PFO
leading to additional risk of systemic embolisation. A literature
review of 88 such patients demonstrated similar mortality
(14%) but higher incidence of stroke in patients treated with
anticoagulation rather than surgical embolectomy.95 Patients
treated with thrombolysis had a much higher mortality (36%),
although they had more haemodynamic compromise. AHA
guidelines therefore recommend surgical embolectomy as the
optimal treatment in this group.
Suggested approach: Thrombolysis is suggested for type A
thrombus while type B thrombus may be treated with anticoagu-
lation alone. Surgical embolectomy is suggested for thrombus
straddling a PFO; if this is not available then anticoagulation
alone is a reasonable approach unless thrombolysis is indicated
due to the severity of the underlying PE. Surgical embolectomy
is suggested for type C thrombus if the thrombus is extremely
large and associated with risk of right atrial or ventricular
outﬂow tract obstruction should it dislodge.
Which patients with acute PE may beneﬁt from an IVC
ﬁlter?
Retrievable IVC ﬁlter insertion in acute PE should be performed
if anticoagulation is contraindicated or temporary cessation of
anticoagulation within 1 month is envisaged. An RCT of IVC
ﬁlter insertion involving 400 patients with proximal DVTreceiv-
ing anticoagulation demonstrated a reduction in subsequent PE,
counterbalanced by an increase in recurrent DVTwith no effect
on mortality.96 97 ACCP guidelines recommend against IVC
ﬁlter insertion in patients with PE receiving anticoagulation,
although they recognise that there is uncertainty regarding the
risk and beneﬁts in patients with hypotension.2 Retrospective
analysis of data collected by the International Cooperative PE
Registry found IVC ﬁlter insertion to be associated with a
reduced 90-day mortality in the setting of massive PE, although
only 10% of patients received IVC ﬁlters and two-thirds of
patients did not receive thrombolysis.98 A large RCT of
retrievable IVC ﬁlter insertion in patients with PE and asso-
ciated DVT (PREPIC-2) has recently been presented in abstract
form.99 No effect on recurrent PE, complications or mortality
was observed.
Suggested approach: We generally limit IVC ﬁlter use in acute
PTE to the small number of patients in whom anticoagulation is
contraindicated. Routine placement of IVC ﬁlters in submassive
PE and proximal DVT is not supported by current evidence. If
possible we use retrievable ﬁlters, which should ideally be
removed within the recommended time scale.
How can I differentiate between acute and chronic PE?
It is not infrequent to see patients with signiﬁcant proximal
chronic thromboembolic disease who have erroneously been
thrombolysed. Several factors may suggest chronic rather than
acute PE. Long duration of symptoms, a previous VTE, features
of pulmonary hypertension on examination in the absence
of systemic hypotension and or tachycardia and bilateral
bruits due to stenoses (appreciated during breath hold on
auscultation) favour a chronic process.100 Electrocardiographic
and echocardiographic changes indicating longstanding
increased RV afterload include a dominant R wave in V1 with
absence of tachycardia and a systolic pulmonary artery pressure
>60 mm Hg on echocardiography (the RV cannot acutely gen-
erate a higher pressure).101 McConnell’s sign (RV free wall
hypokinesis with preserved RV apical contraction) and the
‘60/60’ sign (pulmonary acceleration time below 60 ms with a
tricuspid gradient of 30–60 mm Hg on echocardiography)
suggest acute rather than chronic PE.56 57 An increased RV–LV
ratio may be present in acute and chronic thromboembolic
disease but the presence of RV hypertrophy and large bronchial
arteries are suggestive of chronic disease.102 Within the pulmon-
ary arteries, mural calciﬁed thrombus forming an obtuse angle
with the vessel wall, completely stenosed and narrowed segmen-
tal vessels and signs of recanalisation with contrast ﬂowing
either side of ‘webs’ of organised thrombi are suggestive of
chronic disease.103 Within the parenchyma, peripheral wedge-
shaped infarcts may be present in acute PE while a mosaic per-
fusion pattern with reduction in pulmonary arterial size in low
attenuation areas of the lung suggests chronic disease.
Suggested approach: A chronic history, markedly elevated sys-
tolic pulmonary arterial pressures, RV and bronchial artery hyper-
trophy, thrombus calciﬁcation, webs and a mosaic perfusion
pattern should raise suspicion of chronic rather than acute PE.
In which patients should I consider early discharge?
Clinical severity scoring systems have more clearly identiﬁed
patients at low risk of complications from acute PE who may
not require hospitalisation. PESI is the most widely validated
scoring system and has been utilised in prospective randomised
management studies to demonstrate the safety of such an
approach, which may be appropriate in up to 40% of
patients.104 105 106 Outpatient management of PE generally
requires LMWH administration during oral anticoagulant initi-
ation,105 although the introduction of oral factor Xa inhibitors
provides the possibility of a more convenient ambulatory treat-
ment for patients.107 108 Safe early discharge of patients is
dependent on a robust multidisciplinary approach involving
rapid imaging, accurate assessment and adequate support and
follow-up mechanisms for the discharged patient. Admission of
patients at very low or low risk may still be advisable due to
patient concern or ongoing pain. Repeat PESI scoring after 48 h
in patients initially assessed as unsuitable for discharge may
reclassify them as appropriate for outpatient anticoagulation.109
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Suggested approach: Patients with a very low or low PESI
score may be offered early discharge and outpatient anticoagula-
tion but a robust system of support and follow-up is mandatory.
What is the role of the newer oral agents in the
management of acute PE?
At the time of writing, rivaroxaban, a direct Xa inhibitor, is the
only new oral anticoagulant (NOAC) licensed and approved for
the treatment and secondary prevention of DVT and PE in the
UK.108 Other NOACs (dabigatran: a direct thrombin inhibitor;
and apixaban and edoxaban: direct Xa inhibitors), however, have
also been shown to be non-inferior to conventional anticoagulant
therapy with favourable safety proﬁles in the treatment of
patients with PE. In the dabigatran (RE-COVER)110 and edoxa-
ban (HOKUSAI)111 studies, all patients initially received heparin
for 10 and 7 days. The rivaroxaban (EINSTEIN-PE) and apixa-
ban (AMPLIFY) studies excluded patients who had had more
than 48 h of heparin, thus these therapies introduce the option
of managing patients without parenteral anticoagulation.112 113
Patients with active malignancy were excluded from these studies
(LMWH remains the standard of care for these patients), and
NOACs should not be used in pregnant or lactating women, or in
patients with signiﬁcant renal impairment. Importantly, no
regular monitoring is required.
Suggested approach: Other NOACs may also become licensed
in the future but currently rivaroxaban can be considered an
option for the acute management of haemodynamically stable
patients with PE within its product license.
What should I do about an incidental or isolated
subsegmental PE?
Demonstration of unsuspected PE occurs in up to 5% of thoracic
CT scans performed for non-PE indications, the majority in the
context of malignancy.114–118 In malignancy, most incidental PEs
are lobar or segmental in distribution while VTE recurrence rate,
mortality and complications are not signiﬁcantly different
between incidental and symptomatic PE.119 The ACCP guide-
lines suggest asymptomatic PE should be treated as symptomatic
PE.2 Isolated subsegmental PEs are demonstrated in 1–5% of
CTPAs performed for suspected PE and 10% of CTPAs with
demonstrable PE.114 120–122 Optimal management of these
patients is unclear. Pooled data from 105 patients with predomin-
antly isolated subsegmental PE with no evidence of DVT on
serial imaging who did not receive anticoagulation found no
patients with recurrent PE after 3 months.120 The authors there-
fore suggested that the risk of haemorrhage may outweigh the
beneﬁt of anticoagulation in isolated PE, assuming negative serial
compression ultrasound of lower limb veins.120 This approach
has been challenged by a large prospective study which found
similar risk factors and recurrence rates in patients with symp-
tomatic subsegmental versus more proximal PE, although it is
unclear how many patients had a single subsegmental PE.123
Suggested approach: Incidental and isolated subsegmental PE
should generally be managed in the same manner as symptom-
atic and non-subsegmental PE.
CONCLUSION
The suggested approaches are based on a review of the available
evidence and guidelines and on our clinical experience. For
many of the dilemmas the evidence base is not substantial and is
potentially hampered by reporting bias. Management in an indi-
vidual patient will require clinical assessment of risks and bene-
ﬁts and will also depend on local availability of therapeutic
interventions.
Contributors RC and DGK conceived the article. All authors wrote sections and
reviewed the whole of the manuscript.
Competing interests RC and DGK have received funding for conference
attendance and honoraria for advisory boards and lecturing from Bayer and GSK,
funding for conference attendance from Pﬁzer and their unit has received an
unrestricted educational grant to part-fund a radiographer from Bayer. CAE has
received funding for conference attendance and honoraria for lecturing from Bayer,
and for conference attendance and honoraria for advisory boards and lecturing from
GSK. JH has received funding for conference attendance and honoraria for advisory
boards from Bayer. RJH has received honoraria for advisory boards and lecturing
from Bayer, Boehringer Ingelheim and Sanoﬁ Aventis. RMM has received funding to
attend meetings from Daiichi-Sankyo, Bayer and Boehringer Ingelheim, and received
honoraria for advisory board meetings and/or delivering educational sessions for
Bayer, Daiichi-Sankyo and Pﬁzer. IS receives an annual unrestricted educational grant
from GSK to support a clinical meeting. JVV has received funding to attend meetings
from Boehringer Ingelheim and honoraria for advisory boards from Bayer.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/
REFERENCES
1 Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and
management of acute pulmonary embolism: the Task Force for the Diagnosis and
Management of Acute Pulmonary Embolism of the European Society of Cardiology
(ESC). Eur Heart J 2008;29:2276–315.
2 Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College
of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:
e419S–94S.
3 Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive
pulmonary embolism, iliofemoral deep vein thrombosis, and chronic
thromboembolic pulmonary hypertension: a scientiﬁc statement from the American
Heart Association. Circulation 2011;123:1788–830.
4 Howard L. Thrombolytic therapy for submassive PE? PRO viewpoint. Thorax
2014;69:103–5.
5 Simpson J. Thrombolytic therapy for submassive PE? CON viewpoint. Thorax
2014;69:105–7.
6 Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with
heparin alone in patients with submassive pulmonary embolism. N Engl J Med
2002;347:1143–50.
7 Fasullo S, Scalzo S, Maringhini G, et al. Six-month echocardiographic study in
patients with submassive pulmonary embolism and right ventricle dysfunction:
comparison of thrombolysis with heparin. Am J Med Sci 2011;341:33–9.
8 Riera-Mestre A, Jimenez D, Muriel A, et al. Thrombolytic therapy and outcome of
patients with an acute symptomatic pulmonary embolism. J Thromb Haemost
2012;10:751–9.
9 Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic
model for pulmonary embolism. Am J Respir Crit Care Med 2005;172:1041–6.
10 Jimenez D, Aujesky D, Diaz G, et al. Prognostic signiﬁcance of deep vein
thrombosis in patients presenting with acute symptomatic pulmonary embolism.
Am J Respir Crit Care Med 2010;181:983–91.
11 Jimenez D, Aujesky D, Moores L, et al. Combinations of prognostic tools for
identiﬁcation of high-risk normotensive patients with acute symptomatic
pulmonary embolism. Thorax 2011;66:75–81.
12 Konstantinides S; on behalf of the PEITHO investigators. Fibrinolysis for
normotensive patients with acute submassive pulmonary embolism.
http://clinicaltrialresults.org/Slides/ACC%202013/Konstantinides_PEITHO_ACC%
202013.pdf (accessed Nov 2013).
13 Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated
with poor outcome in patients with stroke. Stroke 2010;41:1450–8.
14 Eckardt J, Licht PB. Successful thrombolysis of major pulmonary embolism 5 days
after lobectomy. Interact Cardiovasc Thorac Surg 2012;14:660–1.
15 Kameyama K, Huang CL, Liu D, et al. Pulmonary embolism after lung resection:
diagnosis and treatment. Ann Thorac Surg 2003;76:599–601.
16 Sakuragi T, Sakao Y, Furukawa K, et al. Successful management of acute pulmonary
embolism after surgery for lung cancer. Eur J Cardiothorac Surg 2003;24:580–7.
17 Zhang K, Zeng X, Zhu C, et al. Successful thrombolysis in postoperative patients
with acute massive pulmonary embolism. Heart Lung Circ 2012 Published Online
First 12 October 2012 doi:10.1016/j.hlc.2012.08.055
18 Girard P, Baldeyrou P, Le Guillou JL, et al. Thrombolysis for life-threatening
pulmonary embolism 2 days after lung resection. Am Rev Respir Dis
1993;147:1595–7.
178 Condliffe R, et al. Thorax 2014;69:174–180. doi:10.1136/thoraxjnl-2013-204667
Review
19 Martin SL, Tellez MG. Utilization of alteplase in trauma victim with an open
abdomen. J Emerg Trauma Shock 2011;4:427–9.
20 Sayeed RA, Nashef SA. Successful thrombolysis for massive pulmonary embolism
after pulmonary resection. Ann Thorac Surg 1999;67:1785–7.
21 Schefﬂer M, Menges T, Zorb C, et al. Successful thrombolysis of a massive
pulmonary embolism following pneumonectomy. Anaesthesist 2008;57:355–8.
22 Ezzet KA. Reversal of acute ischemic stroke after THA using tissue plasminogen
activator. Orthopedics 2013;36:e676–8.
23 Klaus S, Bahlmann L, Mierisch C, et al. Early postoperative thrombolytic therapy
after laparotomy. Resuscitation 2001;50:353–5.
24 Ruiz-Bailen M, Narbona-Carvo B, Ramos-Cuadra JA, et al. Systemic thrombolysis
for prosthetic valve thrombosis in the immediate postoperative period of major
abdominal surgery. J Thorac Cardiovasc Surg 2007;133:801–3.
25 Severi P, Lo Pinto G, Poggio R, et al. Urokinase thrombolytic therapy of pulmonary
embolism in neurosurgically treated patients. Surg Neurol 1994;42:469–70.
26 Weiner RA, Daskalakis M, Theodoridou S, et al. Systemic thrombolysis for acute
massive pulmonary embolism in the immediate postoperative period after bariatric
surgery. Surg Obes Relat Dis 2009;5:271–4.
27 Ayad S, Tetzlaff JE. Massive pulmonary embolism in a patient undergoing
Cesarean delivery. J Clin Anesth 2012;24:582–5.
28 Mick SL. Thrombolytic therapy following rhytidectomy and blepharoplasty. Plast
Reconstr Surg 2004;113:19e–24e.
29 Seifert CL, Sprenger T, Mucke T, et al. Systemic thrombolysis in ischemic stroke
after recent oral surgery and management of oral cavity bleeding. Ann Emerg Med
2011;57:517–19.
30 Wenk M, Popping DM, Hillyard S, et al. Intraoperative thrombolysis in a patient
with cardiopulmonary arrest undergoing caesarean delivery. Anaesth Intensive Care
2011;39:671–4.
31 Cable DG, Cherry KJ. Systemic thrombolytic therapy after recent abdominal
aortic aneurysm repair: an absolute contraindication? Mayo Clin Proc
2003;78:99–102.
32 Gough-Palmer A, Harman F. Bilateral intraorbital haematomata following
thrombolysis for pulmonary embolism. Eye 2009;23:987–9.
33 Leong JK. Orbital haemorrhage complication following postoperative thrombolysis.
Br J Ophthalmol 2003;87:655–6.
34 Lopez-Yunez AM, Bruno A, Williams LS, et al. Protocol violations in
community-based rTPA stroke treatment are associated with symptomatic
intracerebral hemorrhage. Stroke 2001;32:12–16.
35 Wilson AT, Woodmansey PA, Channer KS. Thrombolysis for postoperative
pulmonary embolism. Lancet 1992;340:492.
36 Schmidt KI, Fries P, Feldner SK, et al. Successful thrombolysis after pulmonary
endarterectomy. Ann Thorac Surg 2010;90:2051–3.
37 Wright HJ, Campbell R, Ellis S, et al. Thrombolysis for postoperative pulmonary
embolism: limiting the risk of haemorrhage. Thorax 2010;66:452.
38 Etgen T, Steinich I, Gsottschneider L. Thrombolysis for ischemic stroke in patients
with brain tumors. J Stroke Cerebrovasc Dis 2013 Published Online First 11 June
2013 doi:10.1016/j.jstrokecerebrovasdis.2013.05.004
39 Guillan M, Alonso-Canovas A, Garcia-Caldentey J, et al. Off-label intravenous
thrombolysis in acute stroke. Eur J Neurol 2012;19:390–4.
40 Kondziolka D, Bernstein M, Resch L, et al. Signiﬁcance of hemorrhage into brain
tumors: clinicopathological study. J Neurosurg 1987;67:852–7.
41 Karlinski M, Kobayashi A, Mikulik R, et al. Intravenous alteplase in ischemic stroke
patients not fully adhering to the current drug license in Central and Eastern
Europe. Int J Stroke 2012;7:615–22.
42 Iskander A, Nayak A, Chauhan MS. Submassive pulmonary embolism and
paradoxical embolic stroke treated with percutaneous rheolytic thrombectomy and
closure of the patent foramen ovale. Catheter Cardiovasc Interv 2005;64:356–60.
43 Pavesi PC, Pedone C, Crisci M, et al. Concomitant submassive pulmonary
embolism and paradoxical embolic stroke after a long ﬂight: which is the optimal
treatment? J Cardiovasc Med 2008;9:1070–3.
44 Kelly J, Rudd A, Lewis R, et al. Venous thromboembolism after acute stroke.
Stroke 2001;32:262–7.
45 Mudd PD, James MA. Anticoagulation for atrial ﬁbrillation: should warfarin be
temporarily stopped or continued after acute cardioembolic stroke? Age Ageing
2010;39:670–3.
46 Hallevi H, Albright KC, Martin-Schild S, et al. The complications of cardioembolic
stroke: lessons from the VISTA database. Cerebrovasc Dis 2008;26:38–40.
47 Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain
tissue: asymptomatic or symptomatic? Stroke 2001;32:1330–5.
48 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a
randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435
patients with acute ischaemic stroke. Lancet 1997;349:1569–81.
49 Camerlingo M, Salvi P, Belloni G, et al. Intravenous heparin started within the ﬁrst
3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric
cerebral infarctions. Stroke 2005;36:2415–20.
50 Bath P, Leonardi-Bee J, Bath F. Low molecular weight heparin versus aspirin for acute
ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2002;11:55–62.
51 Swain S, Turner C, Tyrrell P, et al. Diagnosis and initial management of acute
stroke and transient ischaemic attack: summary of NICE guidance. BMJ 2008;337:
a786.
52 Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of
patients with acute ischemic stroke: a guideline for healthcare professionals from
the American Heart Association/American Stroke Association. Stroke
2013;44:870–947.
53 Alteplase spc. http://www.medicines.org.uk/emc/document.aspx?documentId=308
(accessed Nov 2013).
54 Shariﬁ M, Bay C, Skrocki L, et al. Moderate pulmonary embolism treated with
thrombolysis (from the ‘MOPETT’ Trial). Am J Cardiol 2013;111:273–7.
55 Wang C, Zhai Z, Yang Y, et al. Efﬁcacy and safety of low dose recombinant
tissue-type plasminogen activator for the treatment of acute pulmonary
thromboembolism: a randomized, multicenter, controlled trial. Chest
2010;137:254–62.
56 McConnell MV, Solomon SD, Rayan ME, et al. Regional right ventricular
dysfunction detected by echocardiography in acute pulmonary embolism. Am J
Cardiol 1996;78:469–73.
57 Kurzyna M, Torbicki A, Pruszczyk P, et al. Disturbed right ventricular ejection
pattern as a new Doppler echocardiographic sign of acute pulmonary embolism.
Am J Cardiol 2002;90:507–11.
58 Perrott J, Henneberry RJ, Zed PJ. Thrombolytics for cardiac arrest: case report and
systematic review of controlled trials. Ann Pharmacother 2010;44:2007–13.
59 Er F, Nia AM, Gassanov N, et al. Impact of rescue-thrombolysis during
cardiopulmonary resuscitation in patients with pulmonary embolism. PLoS ONE
2009;4:e8323.
60 Ruiz-Bailen M, Aguayo-de-Hoyos E, Serrano-Corcoles MC, et al. Thrombolysis with
recombinant tissue plasminogen activator during cardiopulmonary resuscitation in
fulminant pulmonary embolism. A case series. Resuscitation 2001;51:97–101.
61 British Thoracic Society guidelines for the management of suspected acute
pulmonary embolism. Thorax 2003;58:470–83.
62 Kadner A, Schmidli J, Schonhoff F, et al. Excellent outcome after surgical
treatment of massive pulmonary embolism in critically ill patients. J Thorac
Cardiovasc Surg 2008;136:448–51.
63 Bottiger BW, Arntz HR, Chamberlain DA, et al. Thrombolysis during resuscitation
for out-of-hospital cardiac arrest. N Engl J Med 2008;359:2651–62.
64 Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive
pulmonary embolism: results in 47 consecutive patients after rapid diagnosis
and aggressive surgical approach. J Thorac Cardiovasc Surg 2005;129:
1018–23.
65 Todoran TM, Sobieszczyk P. Catheter-based therapies for massive pulmonary
embolism. Prog Cardiovasc Dis 2010;52:429–37.
66 Kuo WT, Gould MK, Louie JD, et al. Catheter-directed therapy for the treatment of
massive pulmonary embolism: systematic review and meta-analysis of modern
techniques. J Vasc Interv Radiol 2009;20:1431–40.
67 Stein PD, Alnas M, Beemath A, et al. Outcome of pulmonary embolectomy. Am J
Cardiol 2007;99:421–3.
68 Vohra HA, Whistance RN, Mattam K, et al. Early and late clinical outcomes of
pulmonary embolectomy for acute massive pulmonary embolism. Ann Thorac Surg
2011;90:1747–52.
69 Greelish JP, Leacche M, Solenkova NS, et al. Improved midterm outcomes for type
A (central) pulmonary emboli treated surgically. J Thorac Cardiovasc Surg
2011;142:1423–9.
70 Aymard T, Kadner A, Widmer A, et al. Massive pulmonary embolism: surgical
embolectomy versus thrombolytic therapy—should surgical indications be
revisited? Eur J Cardiothorac Surg 2013;43:90–4.
71 Daniels LB, Parker JA, Patel SR, et al. Relation of duration of symptoms with
response to thrombolytic therapy in pulmonary embolism. Am J Cardiol
1997;80:184–8.
72 Meneveau N, Seronde MF, Blonde MC, et al. Management of unsuccessful
thrombolysis in acute massive pulmonary embolism. Chest
2006;129:1043–50.
73 Smulders YM. Pathophysiology and treatment of haemodynamic instability in acute
pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc
Res 2000;48:23–33.
74 Szold O, Khoury W, Biderman P, et al. Inhaled nitric oxide improves pulmonary
functions following massive pulmonary embolism: a report of four patients and
review of the literature. Lung 2006;184:1–5.
75 Kline JA, Hernandez J, Garrett JS, et al. Pilot study of a protocol to administer
inhaled nitric oxide to treat severe acute submassive pulmonary embolism. Emerg
Med J 2013 Published Online First 13 April 2013 doi:10.1136/
emermed-2013-202426
76 Webb SA, Stott S, van Heerden PV. The use of inhaled aerosolized prostacyclin
(IAP) in the treatment of pulmonary hypertension secondary to pulmonary
embolism. Intensive Care Med 1996;22:353–5.
77 Idrees MM, Batubara E, Kashour T. Novel approach for the management of
sub-massive pulmonary embolism. Ann Thorac Med 2012;7:157–61.
Condliffe R, et al. Thorax 2014;69:174–180. doi:10.1136/thoraxjnl-2013-204667 179
Review
78 Kooter AJ, Ijzerman RG, Kamp O, et al. No effect of epoprostenol on right
ventricular diameter in patients with acute pulmonary embolism: a randomized
controlled trial. BMC Pulm Med 2010 10:18.
79 Galea M, Quiney N. Sildenaﬁl in acute pulmonary embolism: case report and
review of literature. J Inten Care Soc 2009;10:44–5.
80 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis
and treatment of venous thromboembolism in pregnancy: a systematic review of
safety and efﬁcacy. Blood 2005;106:401–7.
81 Shaul WL, Hall JG. Multiple congenital anomalies associated with oral
anticoagulants. Am J Obstet Gynecol 1977;127:191–8.
82 RCOG. The acute management of thrombosis and embolism during pregnancy and
the puerperium. http://www.rcog.org.uk/ﬁles/rcog-corp/GTG37b_230611.pdf
(accessed Nov 2013).
83 Gartman EJ. The use of thrombolytic therapy in pregnancy. Obstet Med
2013;6:105–11.
84 O’Keeffe SA, McGrath A, Ryan JM, et al. Management of a massive pulmonary
embolism in a pregnant patient with mechanical fragmentation followed by
delayed catheter-directed thrombolysis in the early postpartum period. J Matern
Fetal Neonatal Med 2008;21:591–4.
85 Taniguchi S, Fukuda I, Minakawa M, et al. Emergency pulmonary embolectomy
during the second trimester of pregnancy: report of a case. Surg Today
2008;38:59–61.
86 Torbicki A, Galie N, Covezzoli A, et al. Right heart thrombi in pulmonary
embolism: results from the International Cooperative Pulmonary Embolism Registry.
J Am Coll Cardiol 2003;41:2245–51.
87 Chartier L, Bera J, Delomez M, et al. Free-ﬂoating thrombi in the right heart:
diagnosis, management, and prognostic indexes in 38 consecutive patients.
Circulation 1999;99:2779–83.
88 Chapoutot L, Nazeyrollas P, Metz D, et al. Floating right heart thrombi and
pulmonary embolism: diagnosis, outcome and therapeutic management.
Cardiology 1996;87:169–74.
89 Mansencal N, Attias D, Caille V, et al. Computed tomography for the detection of
free-ﬂoating thrombi in the right heart in acute pulmonary embolism. Eur Radiol
2011;21:240–5.
90 Ferrari E, Benhamou M, Berthier F, et al. Mobile thrombi of the right heart in
pulmonary embolism: delayed disappearance after thrombolytic treatment. Chest
2005;127:1051–3.
91 European Working Group on Echocardiography. The European Cooperative Study
on the clinical signiﬁcance of right heart thrombi. Eur Heart J 1989;10:
1046–59.
92 Finlayson GN. Right heart thrombi: consider the cause. Can J Cardiol 2008;24:888.
93 Ruiz-Bailen M, Lopez-Caler C, Castillo-Rivera A, et al. Giant right atrial thrombi
treated with thrombolysis. Can J Cardiol 2008;24:312–14.
94 Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest
2002;121:806–14.
95 Fauveau E, Cohen A, Bonnet N, et al. Surgical or medical treatment for thrombus
straddling the patent foramen ovale: impending paradoxical embolism? Report of
four clinical cases and literature review. Arch Cardiovasc Dis 2008;101:
637–44.
96 Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval ﬁlters in
the prevention of pulmonary embolism in patients with proximal deep-vein
thrombosis. Prevention du Risque d’Embolie Pulmonaire par Interruption Cave
Study Group. N Engl J Med 1998;338:409–15.
97 PREPIC study group. Eight-year follow-up of patients with permanent vena cava
ﬁlters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque
d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation
2005;112:416–22.
98 Kucher N, Rossi E, De Rosa M, et al. Massive pulmonary embolism. Circulation
2006;113:577–82.
99 Mismetti P, Ennezat PV, Quere I, et al. Prevention of pulmonary embolism
recurrences by retrievable vena cava ﬁlter: Results of the randomized multicenter
trial PREPIC-2. J Thromb Haemost 2013;11:28.
100 Auger WR, Moser KM. Pulmonary ﬂow murmurs; a distinctive physical sign found
in chronic pulmonary thromboembolic disease. Clin Res 1989;37:145A.
101 Ribeiro A, Lindmarker P, Johnsson H, et al. Pulmonary embolism: one-year
follow-up with echocardiography Doppler and ﬁve-year survival analysis.
Circulation 1999;99:1325–30.
102 Hasegawa I, Boiselle PM, Hatabu H. Bronchial artery dilatation on MDCT scans of
patients with acute pulmonary embolism: comparison with chronic or recurrent
pulmonary embolism. Am J Roentgenol 2004;182:67–72.
103 Castaner E, Gallardo X, Rimola J, et al. Congenital and acquired pulmonary artery
anomalies in the adult: radiologic overview. Radiographics 2006;26:349–71.
104 Donze J, Le Gal G, et al. Prospective validation of the Pulmonary Embolism
Severity Index. A clinical prognostic model for pulmonary embolism. Thromb
Haemost 2008;100:943–8.
105 Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for
patients with acute pulmonary embolism: an international, open-label,
randomised, non-inferiority trial. Lancet 2011;378:41–8.
106 Piran S, Le Gal G, Wells PS, et al. Outpatient treatment of symptomatic pulmonary
embolism: a systematic review and meta-analysis. Thromb Res 2013;132:515–19.
107 Rudd KM, Phillips EL. New oral anticoagulants in the treatment of pulmonary
embolism: efﬁcacy, bleeding risk, and monitoring. Thrombosis 2013 Published
Online First 10 April 2013 doi: org/10.1155/2013/973710
108 National Institute for Health and Care Excellence. Rivaroxiban for treating
pulmonary embolism and preventing recurrent venous thromboembolism.
Technology Appraisal Guidance 287. http://guidance.nice.org.uk/TA287 (accessed
Nov 2013).
109 Moores L, Zamarro C, Gomez V, et al. Changes in PESI scores predict mortality in
intermediate-risk patients with acute pulmonary embolism. Eur Respir J
2013;41:354–9.
110 Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in
the treatment of acute venous thromboembolism. N Engl J Med
2009;361:2342–52.
111 Buller HR, Decousus H, Mercuri M, et al. Edoxaban versus warfarin for the
treatment of symptomatic venous thromboembolism. N Engl J Med
2013;369:1406–15.
112 Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of
symptomatic pulmonary embolism. N Engl J Med 2012;366:1287–97.
113 Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute
venous thromboembolism. N Engl J Med 2013;369:799–808.
114 Ritchie G, McGurk S, McCreath C, et al. Prospective evaluation of unsuspected
pulmonary embolism on contrast enhanced multidetector CT (MDCT) scanning.
Thorax 2007;62:536–40.
115 Gosselin MV, Rubin GD, Leung AN, et al. Unsuspected pulmonary embolism:
prospective detection on routine helical CT scans. Radiology 1998;208:209–15.
116 O’Connell CL, Boswell WD, Duddalwar V, et al. Unsuspected pulmonary emboli
in cancer patients: clinical correlates and relevance. J Clin Oncol
2006;24:4928–32.
117 Douma RA, Kok MG, Verberne LM, et al. Incidental venous thromboembolism in
cancer patients: prevalence and consequence. Thromb Res 2010;125:e306–9.
118 Hui GC, Legasto A, Wittram C. The prevalence of symptomatic and coincidental
pulmonary embolism on computed tomography. J Comput Assist Tomogr
2008;32:783–7.
119 den Exter PL, Hooijer J, Dekkers OM, et al. Risk of recurrent venous
thromboembolism and mortality in patients with cancer incidentally diagnosed
with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol
2011;29:2405–9.
120 Stein PD, Goodman LR, Hull RD, et al. Diagnosis and management of isolated
subsegmental pulmonary embolism: review and assessment of the options.
Clin Appl Thromb Hemost 2012;18:20–6.
121 Le Gal G, Righini M, Parent F, et al. Diagnosis and management of subsegmental
pulmonary embolism. J Thromb Haemost 2006;4:724–31.
122 Carrier M, Righini M, Wells PS, et al. Subsegmental pulmonary embolism
diagnosed by computed tomography: incidence and clinical implications.
A systematic review and meta-analysis of the management outcome studies.
J Thromb Haemost 2010;8:1716–22.
123 den Exter PL, van Es J, Klok FA, et al. Risk proﬁle and clinical outcome of
symptomatic subsegmental acute pulmonary embolism. Blood 2013;122:1144–9.
180 Condliffe R, et al. Thorax 2014;69:174–180. doi:10.1136/thoraxjnl-2013-204667
Review
